A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge
Hypercholesterolemia is a condition characterized by total cholesterol levels exceeding 200 mg/dl. A breakthrough in its treatment was the introduction of the first representative of the status - lovastatin. The mechanism of their action relies on inhibition of the activity of 3-hydroxy-3-methylglut...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Polish |
| Published: |
Polish Pharmaceutical Society
2023-10-01
|
| Series: | Farmacja Polska |
| Subjects: | |
| Online Access: | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F5%2F06_SZ_Statyny_n.pdf |
| _version_ | 1797373816414928896 |
|---|---|
| author | Kacper Kossakowski Klaudia Katarzyna Orzechowska Weronika Sikora Wiktoria Grabowska Kornelia Kowalska Radosław Kujawski Kamila Czora-Poczwardowska Michał Szulc Przemysław Łukasz Mikołajczak Joanna Bartkowiak-Wieczorek |
| author_facet | Kacper Kossakowski Klaudia Katarzyna Orzechowska Weronika Sikora Wiktoria Grabowska Kornelia Kowalska Radosław Kujawski Kamila Czora-Poczwardowska Michał Szulc Przemysław Łukasz Mikołajczak Joanna Bartkowiak-Wieczorek |
| author_sort | Kacper Kossakowski |
| collection | DOAJ |
| description | Hypercholesterolemia is a condition characterized by total cholesterol levels exceeding 200 mg/dl. A breakthrough in its treatment was the introduction of the first representative of the status - lovastatin. The mechanism of their action relies on inhibition of the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme responsible for converting HMG-CoA to mevalonic acid, the main substrate in the synthesis of endogenous cholesterol.
The progress of experimental and clinical studies on action statins indicates a number of other biological properties of this group of compounds, and thus their pharmacological potential. The possibility of their use in the pharmacotherapy of cardiovascular diseases, hyperandrogenism in women with polycystic ovary syndrome (PCOS), osteoporosis, type 2 diabetes, neurodegenerative diseases, or cancer has been so far highlighted.
The aim of this paper was to systematize the knowledge of statin drugs in terms of the progress of studies on their biological activity indicating the possibility of their potential use in the treatment of diseases other than those related to the cardiovascular system, along with verification of their safety profile and demonstrated adverse effects (DN) as a result of their intake.
The literature review was conducted by a screening of the following scientific databases - PubMed and Google Scholar (the analysis lasted from March 2022 to February 2023). The keywords used for searching were disease-related and DN-related.
Statins have shown potential to alleviate symptoms of androgen excess in women suffering from polycystic ovary syndrome (PCOS). Studies relating to their effect on the treatment of Alzheimer's disease and dementia indicate a reduction in progressive neurodegenerative changes, and thus suggest their potential use in the prevention and treatment of comorbid cardiovascular disease. Moreover, statins tend to reduce morbidity, increase survival, and alleviate the progression of cancer. The results of studies of the effects of these drugs on the possibility or development of Parkinson's disease, osteoporosis and the etiology of muscle symptoms appear to be inconsistent in the relationship of their benefits to DN. Unfortunately, it seems that they have also led to disturbances in carbohydrate metabolism and increased the risk of type II diabetes mellitus (NODM). Studies on the effect of the nocebo effect during statin therapy on the frequency with which patients experience DN have confirmed the presence of this effect.
Analysis of the collected studies shows considerable potential for expanding the current therapeutic indications of the drugs in question. However, further randomized controlled trials are required to determine the precise effective dose, duration of therapy for a specific statin. |
| first_indexed | 2024-03-08T18:55:54Z |
| format | Article |
| id | doaj.art-7ebeb8dfa10e47a9a438d568b93cbc3b |
| institution | Directory Open Access Journal |
| issn | 0014-8261 |
| language | Polish |
| last_indexed | 2024-03-08T18:55:54Z |
| publishDate | 2023-10-01 |
| publisher | Polish Pharmaceutical Society |
| record_format | Article |
| series | Farmacja Polska |
| spelling | doaj.art-7ebeb8dfa10e47a9a438d568b93cbc3b2023-12-28T12:27:51ZpolPolish Pharmaceutical SocietyFarmacja Polska0014-82612023-10-0179529731510.32383/farmpol/174070174070A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledgeKacper Kossakowski0https://orcid.org/0000-0003-3753-2337Klaudia Katarzyna Orzechowska1https://orcid.org/0009-0000-7013-8740Weronika Sikora2https://orcid.org/0009-0009-4401-1610Wiktoria Grabowska3https://orcid.org/0009-0004-0609-9192Kornelia Kowalska4https://orcid.org/0009-0001-7594-014XRadosław Kujawski5https://orcid.org/0000-0002-2389-0689Kamila Czora-Poczwardowska6https://orcid.org/0000-0003-2873-4746Michał Szulc7https://orcid.org/0000-0003-3295-2789Przemysław Łukasz Mikołajczak8https://orcid.org/0000-0002-1252-6523Joanna Bartkowiak-Wieczorek9https://orcid.org/0000-0002-8347-0512Studenckie Koło Naukowe Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaStudenckie Koło Naukowe Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaStudenckie Koło Naukowe Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaStudenckie Koło Naukowe Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaStudenckie Koło Naukowe Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaKatedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaKatedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaKatedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaKatedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaKatedra i Zakład Fizjologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, PolskaHypercholesterolemia is a condition characterized by total cholesterol levels exceeding 200 mg/dl. A breakthrough in its treatment was the introduction of the first representative of the status - lovastatin. The mechanism of their action relies on inhibition of the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme responsible for converting HMG-CoA to mevalonic acid, the main substrate in the synthesis of endogenous cholesterol. The progress of experimental and clinical studies on action statins indicates a number of other biological properties of this group of compounds, and thus their pharmacological potential. The possibility of their use in the pharmacotherapy of cardiovascular diseases, hyperandrogenism in women with polycystic ovary syndrome (PCOS), osteoporosis, type 2 diabetes, neurodegenerative diseases, or cancer has been so far highlighted. The aim of this paper was to systematize the knowledge of statin drugs in terms of the progress of studies on their biological activity indicating the possibility of their potential use in the treatment of diseases other than those related to the cardiovascular system, along with verification of their safety profile and demonstrated adverse effects (DN) as a result of their intake. The literature review was conducted by a screening of the following scientific databases - PubMed and Google Scholar (the analysis lasted from March 2022 to February 2023). The keywords used for searching were disease-related and DN-related. Statins have shown potential to alleviate symptoms of androgen excess in women suffering from polycystic ovary syndrome (PCOS). Studies relating to their effect on the treatment of Alzheimer's disease and dementia indicate a reduction in progressive neurodegenerative changes, and thus suggest their potential use in the prevention and treatment of comorbid cardiovascular disease. Moreover, statins tend to reduce morbidity, increase survival, and alleviate the progression of cancer. The results of studies of the effects of these drugs on the possibility or development of Parkinson's disease, osteoporosis and the etiology of muscle symptoms appear to be inconsistent in the relationship of their benefits to DN. Unfortunately, it seems that they have also led to disturbances in carbohydrate metabolism and increased the risk of type II diabetes mellitus (NODM). Studies on the effect of the nocebo effect during statin therapy on the frequency with which patients experience DN have confirmed the presence of this effect. Analysis of the collected studies shows considerable potential for expanding the current therapeutic indications of the drugs in question. However, further randomized controlled trials are required to determine the precise effective dose, duration of therapy for a specific statin.https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F5%2F06_SZ_Statyny_n.pdfalzheimer's diseasecancerosteoporosisstatinsparkinson's diseasepleiotropic effectposnocebomyopathieshiperandrogenism |
| spellingShingle | Kacper Kossakowski Klaudia Katarzyna Orzechowska Weronika Sikora Wiktoria Grabowska Kornelia Kowalska Radosław Kujawski Kamila Czora-Poczwardowska Michał Szulc Przemysław Łukasz Mikołajczak Joanna Bartkowiak-Wieczorek A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge Farmacja Polska alzheimer's disease cancer osteoporosis statins parkinson's disease pleiotropic effect pos nocebo myopathies hiperandrogenism |
| title | A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge |
| title_full | A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge |
| title_fullStr | A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge |
| title_full_unstemmed | A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge |
| title_short | A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge |
| title_sort | critical look at the new possibilities of therapeutic use of statins a summary of the current state of knowledge |
| topic | alzheimer's disease cancer osteoporosis statins parkinson's disease pleiotropic effect pos nocebo myopathies hiperandrogenism |
| url | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F5%2F06_SZ_Statyny_n.pdf |
| work_keys_str_mv | AT kacperkossakowski acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT klaudiakatarzynaorzechowska acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT weronikasikora acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT wiktoriagrabowska acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT korneliakowalska acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT radosławkujawski acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT kamilaczorapoczwardowska acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT michałszulc acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT przemysławłukaszmikołajczak acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT joannabartkowiakwieczorek acriticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT kacperkossakowski criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT klaudiakatarzynaorzechowska criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT weronikasikora criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT wiktoriagrabowska criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT korneliakowalska criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT radosławkujawski criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT kamilaczorapoczwardowska criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT michałszulc criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT przemysławłukaszmikołajczak criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge AT joannabartkowiakwieczorek criticallookatthenewpossibilitiesoftherapeuticuseofstatinsasummaryofthecurrentstateofknowledge |